Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome

Overview

Journal Mol Cell Proteomics

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2011 Jul 12

PMID 21742799

Citations 23

Authors

Markus Britschgi

Kaspar Rufibach

Sarah L Bauer Huang

Christopher M Clark

Jeffrey A Kaye

Ge Li

Elaine R Peskind

Joseph F Quinn

Douglas R Galasko

Tony Wyss-Coray

Affiliations

Soon will be listed here.

Abstract

The study of chronic brain diseases including Alzheimer's disease in patients is typically limited to brain imaging or psychometric testing. Given the epidemic rise and insufficient knowledge about pathological pathways in sporadic Alzheimer's disease, new tools are required to identify the molecular changes underlying this disease. We hypothesize that levels of specific secreted cellular signaling proteins in cerebrospinal fluid or plasma correlate with pathological changes in the Alzheimer's disease brain and can thus be used to discover signaling pathways altered in the disease. Here we measured 91 proteins of this subset of the cellular communication proteome in plasma or cerebrospinal fluid in patients with Alzheimer's disease and cognitively normal controls to mathematically model disease-specific molecular traits. We found small numbers of signaling proteins that were able to model key pathological markers of Alzheimer's disease, including levels of cerebrospinal fluid β-amyloid and tau, and classify disease in independent samples. Several of these factors had previously been implicated in Alzheimer's disease supporting the validity of our approach. Our study also points to proteins which were previously unknown to be associated with Alzheimer's disease thereby implicating novel signaling pathways in this disorder.

Citing Articles

Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.

Wang Z, Ma Y, Sun Y, Tan L, Wang H, Yu J J Neuroinflammation. 2022; 19(1):316.

PMID: 36578067 PMC: 9798566. DOI: 10.1186/s12974-022-02679-5.

Astrocytes as a Therapeutic Target in Alzheimer's Disease-Comprehensive Review and Recent Developments.

Rodriguez-Giraldo M, Gonzalez-Reyes R, Ramirez-Guerrero S, Bonilla-Trilleras C, Guardo-Maya S, Nava-Mesa M Int J Mol Sci. 2022; 23(21).

PMID: 36362415 PMC: 9654484. DOI: 10.3390/ijms232113630.

Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease.

McAlpine C, Park J, Griciuc A, Kim E, Choi S, Iwamoto Y Nature. 2021; 595(7869):701-706.

PMID: 34262178 PMC: 8934148. DOI: 10.1038/s41586-021-03734-6.

Undulating changes in human plasma proteome profiles across the lifespan.

Lehallier B, Gate D, Schaum N, Nanasi T, Lee S, Yousef H Nat Med. 2019; 25(12):1843-1850.

PMID: 31806903 PMC: 7062043. DOI: 10.1038/s41591-019-0673-2.

Blood-based molecular biomarkers for Alzheimer's disease.

Zetterberg H, Burnham S Mol Brain. 2019; 12(1):26.

PMID: 30922367 PMC: 6437931. DOI: 10.1186/s13041-019-0448-1.

References

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

Soares H, Chen Y, Sabbagh M, Roher A, Rohrer A, Schrijvers E . Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci. 2009; 1180:56-67. DOI: 10.1111/j.1749-6632.2009.05066.x. View

Park J, Lee D, Christakis N, Barabasi A . The impact of cellular networks on disease comorbidity. Mol Syst Biol. 2009; 5:262. PMC: 2683720. DOI: 10.1038/msb.2009.16. View

OBryant S, Xiao G, Barber R, Reisch J, Doody R, Fairchild T . A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010; 67(9):1077-81. PMC: 3069805. DOI: 10.1001/archneurol.2010.215. View

Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S . Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain. 2009; 132(Pt 4):1078-92. DOI: 10.1093/brain/awn331. View

Lucin K, Wyss-Coray T . Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron. 2009; 64(1):110-22. PMC: 2834890. DOI: 10.1016/j.neuron.2009.08.039. View

Dubois B, Feldman H, Jacova C, Cummings J, DeKosky S, Barberger-Gateau P . Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010; 9(11):1118-27. DOI: 10.1016/S1474-4422(10)70223-4. View

Zimmermann-Ivol C, Burkhard P, Le Floch-Rohr J, Allard L, Hochstrasser D, Sanchez J . Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics. 2003; 3(1):66-72. DOI: 10.1074/mcp.M300066-MCP200. View

Fagan A, Head D, Shah A, Marcus D, Mintun M, Morris J . Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009; 65(2):176-83. PMC: 2763631. DOI: 10.1002/ana.21559. View

10.

Zhang J, Sokal I, Peskind E, Quinn J, Jankovic J, Kenney C . CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008; 129(4):526-9. PMC: 2688655. DOI: 10.1309/W01Y0B808EMEH12L. View

11.

Villeda S, Luo J, Mosher K, Zou B, Britschgi M, Bieri G . The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011; 477(7362):90-4. PMC: 3170097. DOI: 10.1038/nature10357. View

12.

Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula L . Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol. 2010; 6:441. PMC: 3018170. DOI: 10.1038/msb.2010.93. View

13.

De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn P . Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010; 67(8):949-56. PMC: 2963067. DOI: 10.1001/archneurol.2010.179. View

14.

Hixson J, Vernier D . Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990; 31(3):545-8. View

15.

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

16.

Hu W, Chen-Plotkin A, Arnold S, Grossman M, Clark C, Shaw L . Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010; 120(3):385-99. PMC: 2982700. DOI: 10.1007/s00401-010-0723-9. View

17.

Wunderlich M, Hanhoff T, Goertler M, Spener F, Glatz J, Wallesch C . Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol. 2005; 252(6):718-24. DOI: 10.1007/s00415-005-0725-z. View

18.

Hu W, Chen-Plotkin A, Arnold S, Grossman M, Clark C, Shaw L . Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010; 119(6):669-78. PMC: 2880811. DOI: 10.1007/s00401-010-0667-0. View

19.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

20.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View